CN1061963A - 用作药物的4-取代的呱啶类 - Google Patents

用作药物的4-取代的呱啶类 Download PDF

Info

Publication number
CN1061963A
CN1061963A CN91105945A CN91105945A CN1061963A CN 1061963 A CN1061963 A CN 1061963A CN 91105945 A CN91105945 A CN 91105945A CN 91105945 A CN91105945 A CN 91105945A CN 1061963 A CN1061963 A CN 1061963A
Authority
CN
China
Prior art keywords
ethyl
compound
formula
phenyl
structure formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN91105945A
Other languages
English (en)
Chinese (zh)
Inventor
T·H·布朗
D·G·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017224A external-priority patent/GB9017224D0/en
Priority claimed from GB919107757A external-priority patent/GB9107757D0/en
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of CN1061963A publication Critical patent/CN1061963A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN91105945A 1990-08-06 1991-08-05 用作药物的4-取代的呱啶类 Pending CN1061963A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909017224A GB9017224D0 (en) 1990-08-06 1990-08-06 Compounds
GB9017224.8 1990-08-06
GB919107757A GB9107757D0 (en) 1991-04-12 1991-04-12 Compounds
GB9107757.8 1991-04-12

Publications (1)

Publication Number Publication Date
CN1061963A true CN1061963A (zh) 1992-06-17

Family

ID=26297463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN91105945A Pending CN1061963A (zh) 1990-08-06 1991-08-05 用作药物的4-取代的呱啶类

Country Status (15)

Country Link
EP (1) EP0542846A1 (enrdf_load_stackoverflow)
JP (1) JPH06500093A (enrdf_load_stackoverflow)
KR (1) KR930701402A (enrdf_load_stackoverflow)
CN (1) CN1061963A (enrdf_load_stackoverflow)
AP (1) AP279A (enrdf_load_stackoverflow)
AU (1) AU8327191A (enrdf_load_stackoverflow)
CA (1) CA2088491A1 (enrdf_load_stackoverflow)
IE (1) IE912759A1 (enrdf_load_stackoverflow)
IL (1) IL99073A0 (enrdf_load_stackoverflow)
MA (1) MA22250A1 (enrdf_load_stackoverflow)
MX (1) MX9100513A (enrdf_load_stackoverflow)
NZ (1) NZ239268A (enrdf_load_stackoverflow)
PT (1) PT98574A (enrdf_load_stackoverflow)
TW (1) TW267164B (enrdf_load_stackoverflow)
WO (1) WO1992002502A1 (enrdf_load_stackoverflow)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
ATE182591T1 (de) * 1991-09-12 1999-08-15 Smithkline Beecham Plc 5-ht4 rezeptor antagonisten
EP0629190A1 (en) * 1992-01-28 1994-12-21 Smithkline Beecham Plc Compounds as calcium channel antagonists
NO300539B1 (no) 1992-11-30 1997-06-16 Sankyo Co alfa,omega-diarylalkanderivater, med terapeutisk aktivitet for behandling og forhindring av sirkulasjonssykdommer og psykoser, og farmasöytiske preparater inneholdende disse derivater
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
WO1995024390A1 (en) * 1994-03-11 1995-09-14 Smithkline Beecham Plc Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
EP0799201B1 (en) * 1994-12-21 2001-09-26 Neurosearch A/S Process for the preparation of substituted 4-ethyl-piperidines
AUPN037195A0 (en) * 1995-01-03 1995-01-27 Australian Nuclear Science & Technology Organisation Piperidine-based sigma receptor ligands
US5981539A (en) * 1995-09-15 1999-11-09 Neurosearch A/S Piperidine compounds as calcium channel blockers
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5843983A (en) * 1996-02-15 1998-12-01 Sankyo Company, Limited Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use
CA2262686A1 (en) * 1996-08-12 1998-02-19 Mark E. Fraley Thrombin inhibitors
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
DE60011755T2 (de) * 1999-04-07 2005-06-30 The University Of Virginia Patent Foundation Calciumkanalblocker als antikrebsmittel
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
CA2422055A1 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0203828D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
AR042628A1 (es) * 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
ATE423111T1 (de) 2003-07-03 2009-03-15 Euro Celtique Sa 2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
FR2872416B1 (fr) 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
ATE532514T1 (de) * 2005-09-23 2011-11-15 Ms Science Corp Piperidin- und piperazinderivate
NZ570078A (en) * 2006-01-27 2011-10-28 Ms Science Corp Piperidine and piperazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031221A (en) * 1974-06-17 1977-06-21 American Hoechst Corporation Method of treating pain and hypertension
EP0077427B1 (fr) * 1981-10-15 1985-05-22 Synthelabo Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique
US4546105A (en) * 1984-09-04 1985-10-08 Hoechst-Roussel Pharmaceuticals Inc. Pyrrolylaminopiperidines, compositions thereof and methods of use
DE3441929A1 (de) * 1984-11-16 1986-05-28 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von substituierten piperidinen
DE3529994A1 (de) * 1985-08-22 1987-02-26 Hoechst Ag Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
FR2636946B1 (fr) * 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
HU207310B (en) * 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives

Also Published As

Publication number Publication date
MA22250A1 (fr) 1992-04-01
TW267164B (enrdf_load_stackoverflow) 1996-01-01
IL99073A0 (en) 1992-07-15
KR930701402A (ko) 1993-06-11
NZ239268A (en) 1994-06-27
WO1992002502A1 (en) 1992-02-20
MX9100513A (es) 1992-04-01
JPH06500093A (ja) 1994-01-06
EP0542846A1 (en) 1993-05-26
AP9100313A0 (en) 1991-10-31
CA2088491A1 (en) 1992-02-07
PT98574A (pt) 1992-06-30
AP279A (en) 1993-08-01
IE912759A1 (en) 1992-02-12
AU8327191A (en) 1992-03-02

Similar Documents

Publication Publication Date Title
CN1061963A (zh) 用作药物的4-取代的呱啶类
CN1024547C (zh) 一类环胺化合物的制备方法
CN1019973C (zh) 哌啶衍生物及其药用盐的制备方法
CN1114596C (zh) 联苯基衍生物
CN1158258C (zh) 肾上腺素能α1B受体拮抗药
CN1073169A (zh) 乙酸衍生物
CN1365359A (zh) 苯并呋喃哌嗪和苯并呋喃基高哌嗪:血清素激动剂
CN1098094A (zh) 芳基取代的杂环
CN1109054A (zh) 噁唑烷-2-酮衍生物
CN1681801A (zh) 喹啉基丙基哌啶衍生物以及其作为抗微生物剂的应用
CN1083475A (zh) 乙酸衍生物
CN87105501A (zh) 新苯氧基乙酸衍生物及其制备方法和含有它作为活性成分的药物组成
CN1062349A (zh) 用作药物的3-取代的呱啶类
CN1286255A (zh) 新的吡啶化合物、其制备方法和含有它们的药物组合物
CN1103534A (zh) 具有抗精神病作用的化合物
CN1079745A (zh) 新的9-氟-7-氧代-7H-吡啶并[1，2，3-d，e][1，4]苯并嗪-6-羧酸及其酯
CN1145361A (zh) 新的喹唑啉化合物和含所述化合物作为活性成分的抗肿瘤剂
CN1407982A (zh) 血清素能苯并呋喃
CN1083055A (zh) 药剂
CN1231466C (zh) 新型哌啶衍生物
CN1170537C (zh) 取代的1-(哌啶-4-基)-3-芳基异硫脲、其制备方法及其在制备药物中的应用
CN1894235A (zh) 用作由因子Ⅶa诱导的凝血因子Xa、IXa和凝血酶形成的抑制剂的N－(4－脒基苄基)－2－烷氧基－2－杂环基乙酰胺
CN1823039A (zh) 氨基磺酸环状氨基苯基酯衍生物
CN1028754C (zh) 喹啉衍生物的制备方法
CN1221404A (zh) 盐酸多奈哌齐的多晶型物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication